HIV PROTECTION THEY DESERVE
*
HPTN 083 (N=4566) and HPTN 084 (N=3244) were randomized, double-blind, controlled trials evaluating the safety and efficacy of APRETUDE every 2 months vs daily oral TRUVADA for HIV-1 prevention in adults at risk of acquiring HIV-1. The primary endpoint of both studies was the rate of incident HIV-1 infections.
†Incident HIV-1 infections: TDF/FTC: 39 in 3193 person-years (1.22/100 person-years) and APRETUDE: 12 in 3211 person-years (0.37/100 person-years).
‡Incident HIV-1 infections: TDF/FTC: 36 in 1946 person-years (1.85/100 person-years) and APRETUDE: 3 in 1960 person-years (0.15/100 person-years).
§Administered as an intramuscular injection by a healthcare professional every 2 months after
CI=confidence interval; HPTN=HIV Prevention Trials Network; HR=hazard ratio; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.
PMUS-CBTWCNT240012
References:
Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016
Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4